DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Parkinsonian patients with orthostatic hypotension and dizziness due to usual antiparkinson therapy have been treated with the precursor amino-acid of noradrenaline, DL-3,4-threo-dihydroxyphenylserine (DL-3,4-threo-DOPS). Oral and intravenous administration improved these side effects significantly. A combined treatment of L-dopa, peripheral decarboxylase inhibitor and DL-3,4-threo-DOPS seems to be of benefit with respect to akinesia and orthostatic hypotension.
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001545:Benserazide / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004244:Dizziness / Q000139:chemically induced / Q000188:drug therapy*; D015103:Droxidopa / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced / Q000188:drug therapy*; D008134:Long-Term Care; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy*; D012694:Serine / Q000031:analogs & derivatives*
D000978:Antiparkinson Agents; D012694:Serine; D001545:Benserazide; D015103:Droxidopa; D009638:Norepinephrine